Figure 2.
Silencing SART1 antagonizes the antiviral activity of IFN-α. (a–c) HepG2 cells were cotransfected with HBV-1.3 and Si-SART1 for 24 h. The cells were then treated with 1000 IU/mL IFN-α for 24 h. 48 h after transfection, the supernatants were collected and assayed for quantification of HBV DNA by real-time PCR, HBeAg, and HBsAg by ELISA. An siRNA-negative control was used as a control. (d) HepG2 cells were transfected with si-SART1. 48 h after transfection, the efficiency of si-SART1 was detected by qRT-PCR and western blot. Means ± SD from three independent experiments performed in triplicate are shown. Student's t-test was used to determine significance of differences between two groups. ∗ p < 0.05, and ∗∗ p < 0.01.
